Moderna Pauses Rare Disease Trials Due to COVID-19

Moderna has paused enrollment for its rare disease clinical trials due to the risk of disruption because of the COVID-19 outbreak.

The company said it has stopped new enrollment and site initiation for its rare disease trials with open IND applications.

Moderna is currently conducting clinical trials of its COVID-19 vaccine candidate, mRNA-1273, in collaboration with the National Institutes of Health.